Xiamen Amoytop Biotech Co., Ltd.

This study tests a new growth hormone drug (inpegsomatropin) against an existing one (givopegsomatropin) in 84 girls with Turner syndrome who are shorter than average. The goal is to see which drug works better at increasing height over 52 weeks. Participants must be between 2 an…

This early-stage study tests a new oral drug called ACT500 in 24 adults who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it. Participants will take the drug once daily for a set period, and researche…

This study tests a new drug called inpegsomatropin in 36 adults with growth hormone deficiency. Participants receive either the drug or a placebo to check safety and how well the drug works. The goal is to see if the drug can help restore normal growth hormone levels and improve …

This early-stage study tests a new oral drug called ACT500 in 24 adults with fatty liver disease (MASLD). The main goal is to check safety and how the drug moves through the body. Participants take one pill daily in different dose groups. The study does not aim to cure the diseas…

This early-stage study will test the safety and tolerability of a new drug called ACT100 in 48 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. This is the first …